← Leaderboards
John David O'Neill
Xylyx Bio, Inc.
$5,914,791
Attributed
$6,759,416
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,759,416 · 6
By mechanism
R44$6,255,874 · 4
R43$503,542 · 2
Top collaborators
- Matthew Dominic Bacchetta1 shared
- Ciara M Shaver1 shared
Others in their field
Other Emerging Leaders on “Small Business Innovation Research Grant”
- Gary Fanger · Rise Therapeutics, Llc$23,463,293
- Molly Wasko · University Of Alabama At Birmingham$18,764,568
- Ashkan Vaziri · Biosensics, Llc$17,149,241
- Bryan L McLaughlin · Micro-Leads, Inc.$11,109,320
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$10,485,488
- Matthew Golden · Maphabit, Inc.$8,701,960
Research focus
Small Business Innovation Research GrantCommercializationTechnological InnovationScientistCellsExtracellular MatrixLungPhysiologicalDisease ModelPharmaceutical PreparationsDrug TestingAnimal ModelDrug DevelopmentPredictive ModelingIn Vitro ModelCostMechanicsPhenotypeStandardizationTissuesIn VitroQuality ControlManufacturing ProcessPharmacologic Substance
Grant awards (13)
Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation$1,266,937
R44 · FY2025 · HL · contact PI
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$967,715
R44 · FY2025 · DK · contact PI
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$966,420
R44 · FY2025 · CA · contact PI
Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development$370,020
R44 · FY2024 · DK · contact PI
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development$295,604
R44 · FY2024 · CA · contact PI
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$961,355
R44 · FY2023 · HL · contact PI
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$109,343
R44 · FY2023 · HL · contact PI
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$70,024
R44 · FY2023 · HL · contact PI
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$950,532
R44 · FY2022 · HL · contact PI
Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development$297,924
R44 · FY2021 · HL · contact PI
Biomimetic lung sealant to rapidly heal pulmonary air leaks, decrease recovery time, and reduce associated costs to the healthcare system,$224,101
R43 · FY2020 · HL · contact PI
Native cell specific microenvironments for improved cell culture$54,875
R43 · FY2019 · HL · contact PI
Fibrotic lung extracellular matrix cell culture substrate to improve predictive in vitro models of pulmonary fibrosis for accelerating drug development towards more effective treatment options$224,566
R43 · FY2018 · HL · contact PI